Status:
COMPLETED
Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
Lead Sponsor:
Monash University
Conditions:
Arthralgia
Eligibility:
FEMALE
40-65 years
Brief Summary
Many women with breast cancer are treated with a class of drugs called aromatase inhibitors (mainly letrozole or anastrozole), which lowers the amount of estrogen being produced in the body. Women on ...
Detailed Description
The mechanism of increased bone loss and fracture risk is clearly related to the depletion of estrogen production in the bone. But why there is a higher rate of reporting arthralgia, fracture and join...
Eligibility Criteria
Inclusion
- Group 1 :
- Aged 40 - 65
- Non-hysterectomised women who have undergone breast surgery
- Women on aromatase inhibitors within preceding 12 weeks
- Group 2 : control group
- Healthy, non-hysterectomised women aged 40-65 .
Exclusion
- Previous knee injury requiring non-weight bearing treatment for \> 24 hrs or surgery (including arthroscopy)
- Inability to complete the study (eg proposed relocation)
- Contraindication to undergoing an MRI including pacemaker, metal sutures, presence of shrapnel, iron filings in eye
- Claustrophobia
- Additional Exclusions for Group 1
- Treatment with tamoxifen for \> 8 weeks prior to commencement
- Knee pain lasting for \>24 hours in the last 5 years (prior to commencement on anastrozole or letrozole)
- Anastrazole or Letrozole therapy for \> 12 weeks
Key Trial Info
Start Date :
May 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
115 Patients enrolled
Trial Details
Trial ID
NCT00111241
Start Date
May 1 2005
End Date
December 1 2011
Last Update
December 14 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Women's Health Research Program, Monash University, The Alfred Hospital
Melbourne, Victoria, Australia, 3004